Prokarium’s vision is that all protein vaccines can be delivered orally. Our Vaxonella® platform enables this, while also being a strong stimulator of all arms of immunity, as well as reducing costs and time for vaccine manufacture. Prokarium is based in Keele and London, UK.
CEO: Ted Fjällman
CSO: Rocky Cranenburgh
CFO: Peter Coleman
Please click here for clinical trial information.